Trial Profile
Phase I Study of the Combination of Trastuzumab Emtansine (T-DM1) and Capecitabine in HER2-Positive Metastatic Breast Cancer and HER2-Positive Locally Advanced/Metastatic Gastric Cancer Patients, Followed by a Randomized, Open-Label Phase II Study of Trastuzumab Emtansine and Capecitabine Versus Trastuzumab Emtansine Alone in HER2-Positive Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRAXHER2
- Sponsors Roche
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.
- 18 Jul 2017 The trial has been completed in Greece. (end date: 2017-05-31).